Shire

Showing 15 posts of 170 posts found.

shirelabsus

Shire to close Hampshire base and relocate jobs, say reports

April 27, 2016
Manufacturing and Production, Research and Development Jobs, Shire, close, factory, hampshire, loss, relocate

Shire is set to cease operations at its site in Basingstoke, Hampshire, by the end of next year and relocate …

shire_image

Shire announces new $400 million biologics plant and 400 new jobs in Ireland

April 18, 2016
Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals

Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver …

shirelogo

Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup

April 7, 2016
Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire

Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …

shire_image_4

Shire wins v Allergan in Lialda patent case

March 30, 2016
Research and Development, Sales and Marketing Allergan, Shire, lialda

A US district court has ruled that Shire’s patent for ulcerative colitis drug Lialda is valid through 2020, leaving Allergan …

shire_image_4

Shire launches long-acting ADHD drug in UK

March 9, 2016
Sales and Marketing ADHD, Shire

Shire has launched its long-acting ADHD drug Intuniv (guanfacine) in the UK, for children and adolescents aged 6-17. The treatment …

shire_image_4

FDA to decide on Shire blockbuster hopeful

February 8, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast

The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …

shire_image

Shire tries again with lifitegrast dry eye FDA application

January 25, 2016
Manufacturing and Production, Sales and Marketing FDA, Shire, dry eye disease, lifitegrast

Shire has resubmitted its New Drug Application (NDA) to the US FDA for its rejected dry eye syndrome drug lifitegrast. …

Shire and Baxalta reach $32 billion merger agreement

January 11, 2016
Manufacturing and Production, Sales and Marketing Baxalta, Shire, mergers, mergers and acquisitions

One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …

Logos

Reports: $32bn Shire takeover of Baxalta close to done deal

January 4, 2016
Sales and Marketing Baxalta, Shire, acquisition, merger

The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to …

Flemming Ornskov

Shire moves to seal Baxalta deal with improved offer

December 22, 2015
Research and Development, Sales and Marketing Baxalta, Flemming Ornskov, Shire

Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …

Ikervis

New treatments to boost dry eye drug market – if approved

November 5, 2015
Sales and Marketing Allergan, Ikervis, Restasis, Shire, cyclosporine, dry eye disease, dry eye syndrome, lifitegrast

The global market for treatments for dry eye syndrome will double in value to an estimated $4.6 billion by 2024, …

Shire

Shire to acquire Dyax in $5.9 billion deal

November 2, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease

Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …

Shire image

New Phase III data puts Shire’s lifitegrast back on track for 2016 launch

October 27, 2015
Research and Development Shire, dry eye disease, lifitegrast

Shire shares rose 6% today as the company reported new positive Phase III trial data for lifitegrast in the treatment …

shire_image_4

Shire reports 7% product sales growth, continues Baxalta pursuit

October 23, 2015
Sales and Marketing Baxalta, Shire

Shire has exceeded market expectations as it reported an 11% rise in Q3 earnings on Friday, driven by product sales, …

Flemming Ornskov

Shire’s dry eye treatment gets a no – for now

October 19, 2015
Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast

Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …

The Gateway to Local Adoption Series

Latest content